Baxter Bros Inc. Sells 1,814 Shares of Johnson & Johnson (NYSE:JNJ)

Baxter Bros Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 51,043 shares of the company’s stock after selling 1,814 shares during the period. Johnson & Johnson comprises about 1.1% of Baxter Bros Inc.’s investment portfolio, making the stock its 25th biggest position. Baxter Bros Inc.’s holdings in Johnson & Johnson were worth $8,272,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in JNJ. GenTrust LLC acquired a new position in Johnson & Johnson during the first quarter worth $230,000. FORVIS Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson by 28.7% in the 1st quarter. FORVIS Wealth Advisors LLC now owns 55,050 shares of the company’s stock valued at $8,708,000 after purchasing an additional 12,286 shares during the period. Kesler Norman & Wride LLC lifted its stake in Johnson & Johnson by 6.3% in the 1st quarter. Kesler Norman & Wride LLC now owns 48,533 shares of the company’s stock valued at $7,678,000 after purchasing an additional 2,864 shares during the last quarter. Cohen Investment Advisors LLC grew its holdings in Johnson & Johnson by 10.0% during the first quarter. Cohen Investment Advisors LLC now owns 19,483 shares of the company’s stock worth $3,082,000 after purchasing an additional 1,773 shares during the period. Finally, Maryland State Retirement & Pension System increased its position in Johnson & Johnson by 0.6% during the first quarter. Maryland State Retirement & Pension System now owns 188,638 shares of the company’s stock worth $27,204,000 after buying an additional 1,204 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Wells Fargo & Company boosted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Citigroup upped their price objective on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Royal Bank of Canada raised their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Finally, Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $175.93.

Johnson & Johnson Trading Up 0.2 %

Shares of JNJ stock opened at $160.13 on Monday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The stock’s fifty day moving average price is $163.31 and its two-hundred day moving average price is $155.59. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a market cap of $385.53 billion, a PE ratio of 23.17, a P/E/G ratio of 2.84 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $2.66 earnings per share. Equities analysts predict that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.10%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.